Costco (NASDAQ:COST) is preparing to launch a new weight-loss program that will allow some patients to get weight-loss drug Ozempic from the retailer’s pharmacy partner.
The new weight-loss program from Costco is being offered as part of its team-up with Sesame. This will allow customers to sign up for a weight-loss subscription service that costs $179 every three months.
The weight-loss service from Sesame includes consultation and help from clinicians. This may also include prescribing patients Ozempic if the situation calls for it. This latest offering builds on a partnership between Costco and Sesame that started last year.
Sesame co-founder and President Michael Botta said the following about the Costco weight-loss program to CNN Business:
“It wasn’t what we initially thought would make sense to offer for Costco members who were coming to Sesame […] But we realized pretty quickly, just by looking at what people were curious about, that there was a clear unmet need here.”
Costco Weight Loss Program Drugs
It’s not just Ozempic that patients can get through the Costco weight-loss program. Other drugs to combat obesity can also be available, including Wegovy, Mounjaro and Zepbound.
COST stock is down 1.3% as of Wednesday morning.
Investors can find more of the most recent stock market stories ready to go below!
We have all of the hottest stock market news that traders need to know about on Wednesday! That includes what’s going on with shares of Intel (NASDAQ:INTC) stock, Vanda Pharmaceuticals (NASDAQ:VNDA) stock and Kintara Therapeutics (NASDAQ:KTRA) stock today. All of that info is ready to go at the following links!
More Wednesday Stock Market News
- INTC Stock Alert: What to Know as the Chip Wars Rock Intel Shares Today
- Why Is Vanda Pharmaceuticals (VNDA) Stock Up 33% Today?
- Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today?
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
